Literature DB >> 11338463

Graves' thyroid ophthalmopathy in Ethiopian patients.

T Teshome1, B Seyoum.   

Abstract

In a prospective study, we evaluated the clinical manifestations, severity, complication and management of Graves' thyroid ophthalmopathy (GTO) in 37 Ethiopian patients. Twenty-seven were females and 10 were males (F:M = 2.7:1). The mean age was 35 years (range 19-70 yrs). The mean duration of ocular symptoms was 33.4 months (range 2-120 months) while the mean duration of hyperthyroid symptoms was 36.2 months (range 6-120 months). GTO was found in 30 (81.1%) hyperthyroid, 1 (2.7%) hypothyroid and 5 (13.5%) euthyroid patients. Upper lid retraction was the most common clinical finding, being detected in 31 (83.8%) of the patients. One (2.7%) patient had marked extraocular muscle involvement, involving the inferior rectus muscle of one eye. Though 18 (48.6) patients had signs of soft tissue inflammation, only 4 (10.8%) required the administration of systemic steroids to control the inflammatory process. None of our patients had sight loss from the complications of GTO. Larger prospective studies are suggested to evaluate both the prevalence and possible racial difference in its clinical presentation.

Entities:  

Mesh:

Year:  2001        PMID: 11338463

Source DB:  PubMed          Journal:  Ethiop Med J        ISSN: 0014-1755


  3 in total

1.  Effect of near-total thyroidectomy on thyroid orbitopathy due to toxic goiter.

Authors:  Yasser A Elsayed; Atif M Abdul-Latif; Mukhtar F Abu-Alhuda; Hosam A-F Halim
Journal:  World J Surg       Date:  2009-04       Impact factor: 3.352

2.  Prevalence of increased intraocular pressure in patients with Graves' ophthalmopathy and association with ophthalmic signs and symptoms in the north-west of Iran.

Authors:  Fatemeh Eslami; Shiva Borzouei; Elham Khanlarzadeh; Shiva Seif
Journal:  Clin Ophthalmol       Date:  2019-07-25

Review 3.  Update on thyroid eye disease: Regional variations in prevalence, diagnosis, and management.

Authors:  Caroline Y Yu; Rebecca L Ford; Sara T Wester; Erin M Shriver
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.